Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma.

Pruss M, Dwucet A, Tanriover M, Hlavac M, Kast RE, Debatin KM, Wirtz CR, Halatsch ME, Siegelin MD, Westhoff MA, Karpel-Massler G.

Br J Cancer. 2020 Mar 2. doi: 10.1038/s41416-020-0759-0. [Epub ahead of print]

PMID:
32115576
2.

A New Treatment Opportunity for DIPG and Diffuse Midline Gliomas: 5-ALA Augmented Irradiation, the 5aai Regimen.

Kast RE, Michael AP, Sardi I, Burns TC, Heiland T, Karpel-Massler G, Kamar FG, Halatsch ME.

Brain Sci. 2020 Jan 17;10(1). pii: E51. doi: 10.3390/brainsci10010051.

3.

The Use of Ribavirin as an Anticancer Therapeutic: Will It Go Viral?

Casaos J, Gorelick NL, Huq S, Choi J, Xia Y, Serra R, Felder R, Lott T, Kast RE, Suk I, Brem H, Tyler B, Skuli N.

Mol Cancer Ther. 2019 Jul;18(7):1185-1194. doi: 10.1158/1535-7163.MCT-18-0666. Review.

PMID:
31263027
4.

Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma.

Halatsch ME, Kast RE, Dwucet A, Hlavac M, Heiland T, Westhoff MA, Debatin KM, Wirtz CR, Siegelin MD, Karpel-Massler G.

Br J Pharmacol. 2019 Sep;176(18):3681-3694. doi: 10.1111/bph.14773. Epub 2019 Jul 30.

PMID:
31222722
5.

Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis.

Hlavac M, Dwucet A, Kast RE, Engelke J, Westhoff MA, Siegelin MD, Debatin KM, Wirtz CR, Halatsch ME, Karpel-Massler G.

Cell Oncol (Dordr). 2019 Jun;42(3):287-301. doi: 10.1007/s13402-019-00425-3. Epub 2019 Mar 11.

PMID:
30859392
6.

Augmentation of 5-Aminolevulinic Acid Treatment of Glioblastoma by Adding Ciprofloxacin, Deferiprone, 5-Fluorouracil and Febuxostat: The CAALA Regimen.

Kast RE, Skuli N, Sardi I, Capanni F, Hessling M, Frosina G, Kast AP, Karpel-Massler G, Halatsch ME.

Brain Sci. 2018 Nov 22;8(12). pii: E203. doi: 10.3390/brainsci8120203.

7.

Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment.

Kast RE.

Med Sci (Basel). 2018 Sep 29;6(4). pii: E84. doi: 10.3390/medsci6040084.

8.

Inhibiting the NLRP3 Inflammasome With Methylene Blue as Treatment Adjunct in Myelodysplasia.

Kast RE.

Front Oncol. 2018 Jul 27;8:280. doi: 10.3389/fonc.2018.00280. eCollection 2018.

9.

Ribavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors.

Casaos J, Huq S, Lott T, Felder R, Choi J, Gorelick N, Peters M, Xia Y, Maxwell R, Zhao T, Ji C, Simon T, Sesen J, Scotland SJ, Kast RE, Rubens J, Raabe E, Eberhart CG, Jackson EM, Brem H, Tyler B, Skuli N.

Oncotarget. 2018 Jan 3;9(8):8054-8067. doi: 10.18632/oncotarget.23883. eCollection 2018 Jan 30.

10.

Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen.

Kast RE, Skuli N, Karpel-Massler G, Frosina G, Ryken T, Halatsch ME.

Oncotarget. 2017 Jun 1;8(37):60727-60749. doi: 10.18632/oncotarget.18337. eCollection 2017 Sep 22.

11.

Anti-glioma Activity of Dapsone and Its Enhancement by Synthetic Chemical Modification.

Karpel-Massler G, Kast RE, Siegelin MD, Dwucet A, Schneider E, Westhoff MA, Wirtz CR, Chen XY, Halatsch ME, Bolm C.

Neurochem Res. 2017 Dec;42(12):3382-3389. doi: 10.1007/s11064-017-2378-6. Epub 2017 Aug 29.

PMID:
28852934
12.

The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy.

Kast RE, Skuli N, Cos S, Karpel-Massler G, Shiozawa Y, Goshen R, Halatsch ME.

Breast Cancer (Dove Med Press). 2017 Jul 11;9:495-514. doi: 10.2147/BCTT.S139963. eCollection 2017.

13.

Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin.

Kast RE, Hill QA, Wion D, Mellstedt H, Focosi D, Karpel-Massler G, Heiland T, Halatsch ME.

Tumour Biol. 2017 May;39(5):1010428317699797. doi: 10.1177/1010428317699797. Review.

PMID:
28459367
14.

Doxycycline-loaded coaxial nanofiber coating of titanium implants enhances osseointegration and inhibits Staphylococcus aureus infection.

Song W, Seta J, Chen L, Bergum C, Zhou Z, Kanneganti P, Kast RE, Auner GW, Shen M, Markel DC, Ren W, Yu X.

Biomed Mater. 2017 Jul 5;12(4):045008. doi: 10.1088/1748-605X/aa6a26.

PMID:
28357996
15.

Simultaneous Interference with HER1/EGFR and RAC1 Signaling Drives Cytostasis and Suppression of Survivin in Human Glioma Cells in Vitro.

Karpel-Massler G, Westhoff MA, Kast RE, Dwucet A, Karpel-Massler S, Nonnenmacher L, Siegelin MD, Wirtz CR, Debatin KM, Halatsch ME.

Neurochem Res. 2017 May;42(5):1543-1554. doi: 10.1007/s11064-017-2213-0. Epub 2017 Mar 7.

PMID:
28271323
16.

The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity.

Boccellino M, Quagliuolo L, Alaia C, Grimaldi A, Addeo R, Nicoletti GF, Kast RE, Caraglia M.

Curr Med Res Opin. 2016 Nov;32(11):1839-1848. Epub 2016 Aug 11. Review.

PMID:
27398628
17.

Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ Regimen.

Salacz ME, Kast RE, Saki N, Brüning A, Karpel-Massler G, Halatsch ME.

Onco Targets Ther. 2016 Apr 27;9:2535-45. doi: 10.2147/OTT.S100407. eCollection 2016. Review.

18.

Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.

Kast RE, Ramiro S, Lladó S, Toro S, Coveñas R, Muñoz M.

J Neurooncol. 2016 Feb;126(3):425-31. doi: 10.1007/s11060-015-1996-6. Epub 2015 Nov 24.

PMID:
26603162
19.

Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness.

Kast RE.

Springerplus. 2015 Oct 23;4:638. doi: 10.1186/s40064-015-1441-5. eCollection 2015.

20.

Agomelatine or ramelteon as treatment adjuncts in glioblastoma and other M1- or M2-expressing cancers.

Kast RE.

Contemp Oncol (Pozn). 2015;19(2):157-62. doi: 10.5114/wo.2015.51421. Epub 2015 May 13.

21.
22.

Involvement of MicroRNA in T-Cell Differentiation and Malignancy.

Saki N, Abroun S, Soleimani M, Hajizamani S, Shahjahani M, Kast RE, Mortazavi Y.

Int J Hematol Oncol Stem Cell Res. 2015 Jan 1;9(1):33-49. Review.

23.

Regulatory effect of chemokines in bone marrow niche.

Ahmadzadeh A, Kast RE, Ketabchi N, Shahrabi S, Shahjahani M, Jaseb K, Saki N.

Cell Tissue Res. 2015 Aug;361(2):401-10. doi: 10.1007/s00441-015-2129-4. Epub 2015 Feb 26. Review.

PMID:
25715759
25.

Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.

Karpel-Massler G, Kast RE, Westhoff MA, Dwucet A, Welscher N, Nonnenmacher L, Hlavac M, Siegelin MD, Wirtz CR, Debatin KM, Halatsch ME.

J Neurooncol. 2015 Mar;122(1):21-33. doi: 10.1007/s11060-014-1688-7. Epub 2014 Dec 19.

PMID:
25524815
27.

Raman molecular imaging of brain frozen tissue sections.

Kast RE, Auner GW, Rosenblum ML, Mikkelsen T, Yurgelevic SM, Raghunathan A, Poisson LM, Kalkanis SN.

J Neurooncol. 2014 Oct;120(1):55-62. doi: 10.1007/s11060-014-1536-9. Epub 2014 Jul 20.

PMID:
25038847
28.

Oxidizing to death: disulfiram for cancer cell killing.

Brüning A, Kast RE.

Cell Cycle. 2014;13(10):1513-4. doi: 10.4161/cc.28959. Epub 2014 Apr 22. No abstract available.

29.

Emerging technology: applications of Raman spectroscopy for prostate cancer.

Kast RE, Tucker SC, Killian K, Trexler M, Honn KV, Auner GW.

Cancer Metastasis Rev. 2014 Sep;33(2-3):673-93. doi: 10.1007/s10555-013-9489-6. Review.

PMID:
24510129
30.

Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines.

Karpel-Massler G, Westhoff MA, Kast RE, Dwucet A, Nonnenmacher L, Wirtz CR, Debatin KM, Halatsch ME.

Anticancer Agents Med Chem. 2014 Feb;14(2):313-8.

PMID:
24506460
31.

Raman spectroscopy to distinguish grey matter, necrosis, and glioblastoma multiforme in frozen tissue sections.

Kalkanis SN, Kast RE, Rosenblum ML, Mikkelsen T, Yurgelevic SM, Nelson KM, Raghunathan A, Poisson LM, Auner GW.

J Neurooncol. 2014 Feb;116(3):477-85. doi: 10.1007/s11060-013-1326-9. Epub 2014 Jan 4.

PMID:
24390405
32.

Glioblastoma treatment using perphenazine to block the subventricular zone's tumor trophic functions.

Kast RE, Ellingson BM, Marosi C, Halatsch ME.

J Neurooncol. 2014 Jan;116(2):207-12. doi: 10.1007/s11060-013-1308-y. Epub 2013 Nov 17. Review.

33.

Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells.

Karpel-Massler G, Westhoff MA, Zhou S, Nonnenmacher L, Dwucet A, Kast RE, Bachem MG, Wirtz CR, Debatin KM, Halatsch ME.

Mol Cancer Ther. 2013 Sep;12(9):1783-95. doi: 10.1158/1535-7163.MCT-13-0052. Epub 2013 Jul 5.

34.

A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.

Kast RE, Boockvar JA, Brüning A, Cappello F, Chang WW, Cvek B, Dou QP, Duenas-Gonzalez A, Efferth T, Focosi D, Ghaffari SH, Karpel-Massler G, Ketola K, Khoshnevisan A, Keizman D, Magné N, Marosi C, McDonald K, Muñoz M, Paranjpe A, Pourgholami MH, Sardi I, Sella A, Srivenugopal KS, Tuccori M, Wang W, Wirtz CR, Halatsch ME.

Oncotarget. 2013 Apr;4(4):502-30. Review.

35.

Aldehyde dehydrogenase and HSP90 co-localize in human glioblastoma biopsy cells.

Rappa F, Cappello F, Halatsch ME, Scheuerle A, Kast RE.

Biochimie. 2013 Apr;95(4):782-6. doi: 10.1016/j.biochi.2012.11.007. Epub 2012 Nov 29.

PMID:
23201460
36.

Identification of pediatric brain neoplasms using Raman spectroscopy.

Leslie DG, Kast RE, Poulik JM, Rabah R, Sood S, Auner GW, Klein MD.

Pediatr Neurosurg. 2012;48(2):109-17. doi: 10.1159/000343285. Epub 2012 Nov 15.

PMID:
23154646
37.

Conclusions and data analysis: a 6-year study of Raman spectroscopy of solid tumors at a major pediatric institute.

Auner AW, Kast RE, Rabah R, Poulik JM, Klein MD.

Pediatr Surg Int. 2013 Feb;29(2):129-40. doi: 10.1007/s00383-012-3211-6.

PMID:
23143035
38.

Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide.

Triscott J, Lee C, Hu K, Fotovati A, Berns R, Pambid M, Luk M, Kast RE, Kong E, Toyota E, Yip S, Toyota B, Dunn SE.

Oncotarget. 2012 Oct;3(10):1112-23.

39.

Matrix metalloproteinase-2 and -9 in glioblastoma: a trio of old drugs-captopril, disulfiram and nelfinavir-are inhibitors with potential as adjunctive treatments in glioblastoma.

Kast RE, Halatsch ME.

Arch Med Res. 2012 Apr;43(3):243-7. doi: 10.1016/j.arcmed.2012.04.005. Epub 2012 May 5. Review.

PMID:
22564423
40.

Why dapsone stops seizures and may stop neutrophils' delivery of VEGF to glioblastoma.

Kast RE, Lefranc F, Karpel-Massler G, Halatsch ME.

Br J Neurosurg. 2012 Dec;26(6):813-7. doi: 10.3109/02688697.2012.674577. Epub 2012 May 2. Review.

PMID:
22551309
41.

Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma.

Pala A, Karpel-Massler G, Kast RE, Wirtz CR, Halatsch ME.

Cancers (Basel). 2012 May 8;4(2):523-30. doi: 10.3390/cancers4020523.

42.

Erlotinib in glioblastoma: lost in translation?

Karpel-Massler G, Westhoff MA, Kast RE, Wirtz CR, Halatsch ME.

Anticancer Agents Med Chem. 2011 Oct;11(8):748-55. Review.

PMID:
21707495
43.

The rationale of targeting neutrophils with dapsone during glioblastoma treatment.

Kast RE, Scheuerle A, Wirtz CR, Karpel-Massler G, Halatsch ME.

Anticancer Agents Med Chem. 2011 Oct;11(8):756-61. Review.

PMID:
21707494
44.

Temozolomide modifies caveolin-1 expression in experimental malignant gliomas in vitro and in vivo.

Bruyère C, Abeloos L, Lamoral-Theys D, Senetta R, Mathieu V, Le Mercier M, Kast RE, Cassoni P, Vandenbussche G, Kiss R, Lefranc F.

Transl Oncol. 2011 Apr 1;4(2):92-100.

45.

Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?

Kast RE, Karpel-Massler G, Halatsch ME.

Br J Pharmacol. 2011 Nov;164(5):1393-6. doi: 10.1111/j.1476-5381.2011.01320.x.

46.

Temozolomide-induced modification of the CXC chemokine network in experimental gliomas.

Bruyère C, Mijatovic T, Lonez C, Spiegl-Kreinecker S, Berger W, Kast RE, Ruysschaert JM, Kiss R, Lefranc F.

Int J Oncol. 2011 May;38(5):1453-64. doi: 10.3892/ijo.2011.964. Epub 2011 Mar 8.

PMID:
21399866
49.
50.

Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct.

Söderlund J, Erhardt S, Kast RE.

J Neuroinflammation. 2010 Aug 6;7:44. doi: 10.1186/1742-2094-7-44.

Supplemental Content

Support Center